References to Primary Literature
- KALARIA RN: Cerebral microvasculatttre and immu-nological factors in Alzheimer's disease. din. Neurosci. (1993) 1:204–211.
- SCHENK DB, RYDEL RE et al.: Therapeutic approachesrelated to amyloid [3-peptide and Alzheimer's Disease. J. Med. Chem. (1995) 38.4141–4154.
- CITRON M et al.: Mutation of the [3-amyloid precursorprotein in familial Alzheimer's Disease increases [3-pro-tein production. Nature (1992) 360:672–674.
- SIMMONS LK et al.: Secondary structure of amyloid peptide correlates with neurotoxic activity in vitro. Mol. Pharmacol. (1994) 45:373–379.
References to Patent Literature
- MERRELL DOW PHARMACEUTICALS AND SCIOS NOVA, INC., W09509838 (1995).
- ELI LILLY & CO., INC., EP-94308805.4 (1995).
- ELI LILLY & CO., INC., W09517095 (1995).